EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Experience Using Efgartigimod to Treat Juvenile Myasthenia Gravis in China: A Multicenter Retrospective Study

Jing Lin, Guoyan Qi, Susan Luo iD, Qilong Jiang, Bitao Bu, Min Liu, Yuzhen Wei, Meigui Han, Junhong Yang, Zhilan Zhao, Lili Zhang, Yifan Zhang und 3 weitere

Muscle & Nerve · 2026-06 · 73 (6) · 1025-1031

DOI: 10.1002/mus.70202 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Muscle & Nerve, online erschienen am 07.03.2026. Verfasst von Jing Lin und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Myasthenia Gravis, Immunosuppressive Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Hubei Province, Health Commission of Hubei Province scientific research project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction/Aims Current therapeutic management of juvenile myasthenia gravis (JMG) predominantly relies on conventional immunosuppressive therapies and expert consensus extrapolated from adult data, creating a critical gap in high‐quality, pediatric‐specific clinical evidence. The aim of this study was to assess the efficacy and safety of efgartigimod in the pediatric population.

Methods

This multicenter retrospective study enrolled JMG patients (under 18 years), from 12 Chinese centers, who received at least one dose of efgartigimod. Efgartigimod was administered as weekly intravenous infusions. Study visits included W0 (baseline: pretreatment) and W1–W4 (weekly posttreatment follow‐ups). Efficacy was assessed via MG‐related Activities of Daily Living (MG‐ADL) score, Quantitative Myasthenia Gravis (QMG) score, and the MG Composite (MGC) scale.

Results

Seventeen JMG patients (3 males, 14 females) with a median disease duration of 23 months were included. At W0, 88.2% of patients were classified as Myasthenia Gravis Foundation of America (MGFA) class II–V and were anti‐acetylcholine receptor (anti‐AchR) antibody positive. After efgartigimod treatment, clinically meaningful improvement (CMI) was observed in 70.6% (W1), 73% (W2), and 91.7% (W4); 66.7% achieved minimal symptom expression by W4. MG‐ADL and QMG scores decreased by 30% and 30.1% (W1) and by 87.6% and 71.8% (W4) compared to W0. No treatment‐related adverse events occurred.

Discussion

Our study suggests efgartigimod is an effective therapeutic option for JMG, with favorable efficacy and safety profiles. Further studies are necessary to validate the efficacy and safety of efgartigimod in the pediatric population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myasthenia GravisImmunosuppressive AgentsHumansFemaleMaleRetrospective StudiesChildAdolescentChinaTreatment OutcomeChild, PreschoolActivities of Daily Living

Stichwörter der Autor:innen

efficacyefgartigimodjuvenile myasthenia gravismonoclonal antibodiesneonate fc receptor blockerssafety

Substanzen

Immunosuppressive Agents

Autor:innen und Institutionen

  • Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Neurology, Shijiazhuang City People's Hospital, Shijiazhuang, China.
  • Huashan Rare Disease Center and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Center for Neurological Disorders, Fudan University, Shanghai, China.
  • Department of Neurology, The First Affiliated Hospital of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Department of Neurology, The Affiliated Hospital of Qingdao University, Qingdao, China.
  • Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

ORCID-Profile: Susan Luo, Haoyou Xu, Zhijun Li

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Hubei Province
  • Health Commission of Hubei Province scientific research project

Zitieren

APA

Lin, J., Qi, G., Luo, S., Jiang, Q., Bu, B., Liu, M., Wei, Y., Han, M., Yang, J., Zhao, Z., Zhang, L., Zhang, Y., Xu, H., Hao, X., & Li, Z. (2026). Experience Using Efgartigimod to Treat Juvenile Myasthenia Gravis in China: A Multicenter Retrospective Study. Muscle & Nerve, 73(6), 1025-1031. https://doi.org/10.1002/mus.70202

Vancouver

Lin J, Qi G, Luo S, Jiang Q, Bu B, Liu M, et al. Experience Using Efgartigimod to Treat Juvenile Myasthenia Gravis in China: A Multicenter Retrospective Study. Muscle & Nerve. 2026;73(6):1025-1031. doi:10.1002/mus.70202

BibTeX
@article{Lin2026,
  author = {Lin, Jing and Qi, Guoyan and Luo, Susan and Jiang, Qilong and Bu, Bitao and Liu, Min and Wei, Yuzhen and Han, Meigui and Yang, Junhong and Zhao, Zhilan and Zhang, Lili and Zhang, Yifan and Xu, Haoyou and Hao, Xingjie and Li, Zhijun},
  title = {Experience Using Efgartigimod to Treat Juvenile Myasthenia Gravis in China: A Multicenter Retrospective Study},
  journal = {Muscle & Nerve},
  year = {2026},
  volume = {73},
  number = {6},
  pages = {1025--1031},
  doi = {10.1002/mus.70202}
}
Kostenlos starten →